Tackling chronic migraine: Current perspectives

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 185-194

  Carod Artal, Francisco Javier ^a,b  

^a RAIGMORE HOSPITAL   (United Kingdom)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Chronic daily headache; Chronic migraine; Epidemiology; Medication overuse headache; Risk factors; Treatment

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BOTULINUM TOXIN A; CAFFEINE; FLUNARIZINE; GABAPENTIN; MEMANTINE; NAPROXEN PLUS SUMATRIPTAN; PLACEBO; PREGABALIN; PROPRANOLOL; TIZANIDINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

CARDIOVASCULAR RISK; CHRONIC PAIN; CLINICAL FEATURE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; LIFE STRESS; MENTAL DISEASE; NERVE STIMULATION; OCCIPITAL NERVE STIMULATION; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SNORING; TRANSFORMED MIGRAINE; TREATMENT DURATION;

EID: 84898469637     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S61819     Document Type: Review

References (74)

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. 3rd ed (beta version). Cephalalgia. 2013;33(9):629-808.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia. 2004; 24 Suppl 1:9-160.
3. Headache Classification Committee; Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742-746.
4. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47(4):871-875.
5. Manzoni GC, Bonavita V, Bussone G, et al; ANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee). Chronic migraine classification: current knowledge and future perspectives. J Headache Pain. 2011;12(6):585-592.
6. Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache. 1982; 22(2):66-68.
7. Carod-Artal FJ, Irimia P, Ezpeleta D. [Chronic migraine: definition, epidemiology, risk factors and treatment]. Rev Neurol. 2012;54(10):629-637. Spanish [with English abstract].
8. Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53(1):168-176.
9. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-2196.
10. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70-78.
11. Schramm SH, Obermann M, Katsarava Z, Diener HC, Moebus S, Yoon MS. Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. J Headache Pain. 2013;14(1):40.
12. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10): 1456-1470.
13. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609.
14. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(Suppl 5):S3-S7.
15. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8): 1157-1168.
16. Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011;51(5):693-706.
17. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2010;31(3):301-315.
18. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837-850.
19. Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Value Health. 2013;16(1):31-38.
20. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711-718.
21. Moskowitz MA. The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology. 1991;41(2(Pt 1):182-186.
22. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011;51 Suppl 2:84-92.
23. Maniyar FH, Goadsby PJ. Functional imaging in chronic migraine. Curr Pain Headache Rep. 2013;17(5):333.
24. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62(5):788-790.
25. Louter MA, Bosker JE, van Oosterhout WP, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489-3496.
26. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14): 1191-1196.
27. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432.
28. Guo S, Shalchian S, Gérard P, et al. Prevalence of right-to-left shunts on transcranial Doppler in chronic migraine and medication-overuse headache. Cephalalgia. 2014;34(1):37-41.
29. Fava A, Pirritano D, Consoli D, et al. Chronic migraine in women is associated with insulin resistance: a cross-sectional study. Eur J Neurol. 2014;21(2):267-272.
30. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67(2): 252-257.
31. Carod-Artal FJ, Ezpeleta D, Martín-Barriga ML, Guerrero AL. Triggers, symptoms, and treatment in two populations of migraneurs in Brazil and Spain. A cross-cultural study. J Neurol Sci. 2011;304(1-2):25-28.
32. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4): 644-655.
33. Tepper SJ. Medication-overuse headache. Continuum (Minneap Minn). 2012;18(4):807-822.
34. Schulman E, McGeeney BE. Current concepts in refractory migraine. Curr Treat Options Neurol. 2013;15(1):40-55.
35. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22-33.
36. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814-823.
37. Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153-1162.
38. Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10):1021-1027.
39. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37-41.
40. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470-482.
41. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12): 1753-1759.
42. Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33-51.
43. Aurora SK, Dodick DW, Turkel CC, et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803.
44. Diener HC, Dodick DW, Aurora SK, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30(7):804-814.
45. Aurora SK, Dodick DW, Diener HC, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61-70.
46. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9): 1406-1418.
47. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373.
48. Dodick DW, Turkel CC, DeGryse R, et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6): 921-936.
49. Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain. 2011;12(2):235-238.
50. Batty AJ, Hansen RN, Bloudek LM, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16(7):877-887.
51. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49(10): 1466-1478.
52. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21-32.
53. Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009;32(2): 103-106.
54. Pascual-Gómez J, Gracia-Naya M, Leira R, et al. [Zonisamide in the preventive treatment of refractory migraine]. Rev Neurol. 2010;50: 129-132. Spanish [with English abstract].
55. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35-39.
56. Gracia-Naya M, Ríos C, García-Gomara MJ, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Rev Neurol. 2013;57(8):347-353. Spanish [with English abstract].
57. Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus. 2013;2:479.
58. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9): 1337-1342.
59. Silberstein SD, Dodick DW, Lindblad AS, et al; Chronic Migraine Treatment Trial Research Group. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976-984.
60. Cady R, Nett R, Dexter K, Freitag F, Beach ME, Manley HR. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap. Headache. 2014;54(1):80-93.
61. Calhoun AH, Ford S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache. 2007;47(8):1178-1183.
62. Weeks RE. Application of behavioral therapies in adult and adolescent patients with chronic migraine. Neurol Sci. 2013;34 Suppl 1: S11-S17.
63. Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep. 2013;17(1):304.
64. Powers SW, Kashikar-Zuck SM, Allen JR, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622-2630.
65. Yang CP, Chang MH, Liu PE, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011;31(15):1510-1521.
66. Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14(1):86.
67. Lipton R, Goadsby P, Cady R, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia. 2009;29:30.
68. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ; ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31(3):271-285.
69. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16): 1165-1179.
70. Serra G, Marchioretta F. Occipital nerve stimulation for chronic migraine: a randomized trial. Pain Physician. 2012;15(3):245-253.
71. Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg Focus. 2013;35:E9.
72. Weibelt S, Andress-Rothrock D, King W, Rothrock J. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache. 2010;50(6):1041-1044.
73. Manzoni GC, Camarda C, Torelli P. Chronification of migraine: what clinical strategies to combat it? Neurol Sci. 2013;34 Suppl 1: S57-S60.
74. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26(9):1168-1170.